IMP321: Ph I TACTI-mel ongoing

An independent DSMB recommended continuation of the open-label, Australian Phase I TACTI-mel trial evaluating

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE